HomeCompareRECEF vs GBDC

RECEF vs GBDC: Dividend Comparison 2026

RECEF yields 909.09% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RECEF wins by $8252627.36M in total portfolio value
10 years
RECEF
RECEF
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full RECEF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — RECEF vs GBDC

📍 RECEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRECEFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RECEF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RECEF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RECEF
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, RECEF beats the other by $5,766,862,020,325.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RECEF + GBDC for your $10,000?

RECEF: 50%GBDC: 50%
100% GBDC50/50100% RECEF
Portfolio after 10yr
$4126334.53M
Annual income
$3,392,288,227,395.69/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

RECEF
No analyst data
Altman Z
-148.3
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RECEF buys
0
GBDC buys
0
No recent congressional trades found for RECEF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRECEFGBDC
Forward yield909.09%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$8252648.21M$20.85M
Annual income after 10y$6,784,560,004,057.53$16,450,733.83
Total dividends collected$8138900.96M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: RECEF vs GBDC ($10,000, DRIP)

YearRECEF PortfolioRECEF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$101,609$90,909.09$12,492$1,791.70+$89.1KRECEF
2$972,011$863,288.79$16,527$3,160.58+$955.5KRECEF
3$8,758,157$7,718,105.75$23,588$5,904.90+$8.73MRECEF
4$74,364,546$64,993,317.91$37,141$11,901.65+$74.33MRECEF
5$595,318,755$515,748,691.06$66,205$26,463.38+$595.25MRECEF
6$4,495,664,203$3,858,673,134.79$137,452$66,612.65+$4495.53MRECEF
7$32,043,550,537$27,233,189,840.42$342,372$195,298.53+$32043.21MRECEF
8$215,696,715,677$181,410,116,602.38$1,053,292$686,954.33+$215695.66MRECEF
9$1,372,045,052,584$1,141,249,566,809.58$4,111,439$2,984,416.95+$1372040.94MRECEF
10$8,252,648,210,323$6,784,560,004,057.53$20,849,974$16,450,733.83+$8252627.36MRECEF

RECEF vs GBDC: Complete Analysis 2026

RECEFStock

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Full RECEF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this RECEF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RECEF vs SCHDRECEF vs JEPIRECEF vs ORECEF vs KORECEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.